智飞生物(300122) - 2017 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2017 reached ¥1,342,568,632.76, representing a year-on-year increase of 201.06%[3] - Operating profit amounted to ¥512,240,491.07, showing a significant growth of 1,669.00% compared to the previous year[3] - Net profit attributable to shareholders was ¥432,275,400.68, reflecting a year-on-year increase of 1,229.25%[3] - Basic earnings per share increased to ¥0.27, up 1,250.00% from ¥0.02 in the previous year[3] - The weighted average return on equity rose to 15.85%, an increase of 14.55 percentage points from 1.30%[3] Assets and Equity - Total assets at the end of the reporting period were ¥4,105,898,074.91, a 51.54% increase from the beginning of the period[3] - Shareholders' equity attributable to the company reached ¥2,937,532,367.69, up 16.51% from the beginning of the period[3] - The net asset value per share attributable to shareholders increased to ¥1.84, reflecting a growth of 16.46%[3] Performance Drivers - The significant increase in performance was attributed to the gradual elimination of uncertainties from the 2016 vaccine industry incident and the recovery of vaccine product promotion and sales[5] - There were no discrepancies between the reported performance and the previously disclosed earnings forecast[6]